CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Bay State Extracts

John Nathan, Chief Executive Officer

Strategic Growth in a Rapidly Evolving Hemp Market

John Nathan

John Nathan

Resilient Growth Pathfinder

Shaping Perspective on Hemp and Cannabinoid Industry


Watching the influx of manufacturers shift starkly away from pure THC options and into multi-cannabinoid broad & full spectrum formulations has been the driving force. Seeing the consumer in real time adapt and learn about targeted benefits and effects based products has pushed the cannabis industry to apply more thought and consideration into product formulation rather than seeking to simply get their customers stoned.


The harmony between marijuana and hemp was forged by the hemp industry, leading the charge on the proliferation of minor cannabinoids and ensuring their availability. While they traditionally operated in similar but parallel industries, it’s been beneficial for all sides and the end user to work in unison. They are complementary to each other. The rise in minor cannabinoid formulations has also elevated consumer knowledge and they make more educated spending decisions when selecting all products based on it.


Overcoming Regional Challenges While Advancing Industry Growth


In New England, the primary issue is the high cost of operation and unforgiving climate, coupled with downward pricing pressures. Because hemp is federally legal, there are no restrictions on interstate commerce, allowing out-of-state farmers to grow at exponentially lower costs with two growing seasons versus one here. That pricing pressure translates to unsustainable pricing on hemp biomass and disenfranchises aspiring hemp farmers.


“Seeing the consumer in real time adapt and learn about targeted benefits and effects based products has pushed the cannabis industry to apply more thought and consideration into product formulation.”


By understanding the nuances and recognizing that the word "hemp" wasn't meant to be obfuscated into a legal shield for selling experimental cannabinoids. Many of us are utilizing the low cost of hemp to do beneficial work and supplement the marijuana supply chain with pure extracts intended to bolster product formulations at low costs. There are unfortunately, many bad actors in the hemp space that have conflated the industry with nefarious products intended to skirt THC laws for a quick dollar. It has soured many who are not in tune with how broad the hemp industry is and what it encompasses.


Role of Farmer Partnerships in Supply Chains


Everything. Without a steady supply of crop, this industry does not exist outside of synthetics, which can be "legally" considered hemp in the eyes of the law. They are firmly not hemp, given that the starting material is not directly from the plant.


Finding a way to keep farmers paid well and happy while maintaining the costs expected by the buyers is a delicate balancing act. There have been many types of ebbs and flows, and we have seen a large exodus of hemp farms over the last 3 years.


Preparing for Success in the Hemp Industry


Plan for the worst. Your business plan should accomodate for extreme price fluctuations and pricing pressures. Just CBD isolate alone, I have watched launch at $20k/kg and drop to $100/kg and then rebound back up due to supply shortages. We are at the mercy of biomass availability and when farmers exit and material is horded - it creates an environment that can be stressful.


The market can be a bit chaotic and being able to weather the storm is essential. The key question I would ask is "What is the gap in the market and how am I uniquely qualified to fill it?" - it's a crowded space with a low barrier to entry. Be prepared to find ways to carve out your place.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.

Editorial Lens

Hemp industry leaders face a market where volatile pricing, regional cost pressures and uneven practices can quickly undermine otherwise promising growth plans. John Nathan’s perspective connects commercial resilience with responsible formulation, farmer viability and supply chain discipline, offering decision-makers a grounded view of what sustainable participation requires.

The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/leadership-perspective/john-nathan-nwid-3513.html